Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019693 (HIV)
 170,526 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The topographic diagnosis of facial nerve lesions is based on the symptoms that accompany paralysis, allowing lesions to be located in the protuberance, pontocerebellar angle, facial channel or trajectory distal to the stylomastoid foramen. Most cases of peripheral facial palsy have no apparent cause (idiopathic, or Bell's, peripheral facial palsy). However, facial palsy can sometimes be a manifestation of neuroborreliosis, multiple sclerosis, diabetes, HIV infection or neurinoma. Neurophysiologic studies complement physical examination to establish a prognosis; after the fifth day axonal degeneration related to incomplete recovery can be recognized. Magnetic resonance identifies nerve lesions but is useful only in atypical cases. Prednisone 1 mg/kg over 5 days, with gradual weaning, is the most widely accepted treatment for Bell's palsy. Acyclovir is indicated in Ramsay-Hunt syndrome. Early surgical decompression in cases with poor prognosis is not generally considered beneficial. Cases of permanent facial palsy have serious consequences, particularly because facial expression is altered.
 ...
PMID:[Diagnosis and treatment of facial palsy]. 913 9

A new antiviral drug with both anti-HSV and anti-HIV activity was synthesized by coupling Acyclovir and the acyclic nucleoside phosphonate (R)PMPA. The heterodinucleotide ACVpPMPA encapsulated into autologous erythrocytes was added to human macrophages providing an effective in vitro protection from HSV-1 and HIV-1 replication.
 ...
PMID:Synthesis and biological application of a new heterodinucleotide with both anti-HSV and anti-HIV activity. 1043 27

The rates of herpes simplex virus (HSV) infection are rising, the highest prevalence being in the group infected with the human immunodeficiency virus (HIV). We review the relation between these 2 infections. The presence of genital ulcers increases the transmission of HIV, and the presence of HIV adversely affects the natural history of HSV infection. The detection and treatment of sexually transmitted diseases such as genital herpes actually decrease the rates of HIV infection in groups studied. The treatment of HSV in persons with HIV is challenging because the incidence of immunosuppression increases. Acyclovir resistance is more common in this group, but acyclovir use may prolong survival in some HIV-seropositive patients. Further studies are needed to determine whether persons with HIV disease should routinely be given HSV-specific therapy.
 ...
PMID:Relation between herpes simplex viruses and human immunodeficiency virus infections. 1056 40

Alpha-herpesvirus infections by herpes simplex virus and varicella-zoster virus among HIV-infected patients were summarized. These infections were occurred in a high frequency and shown to be extensive lesions, prolonged virus excretion from the lesions, generalized infection, and uncommon diseases as compared these of with immunocompetent patients. Acyclovir-resistant viruses appeared. These evidences supplied the profound understanding of the pathogenesis and new subjects in the field of herpesvirus infection. Recent introduction of HAART against HIV and the appropriate use of anti-herpesvirus drugs, however, reduced the development of severe infection, and provided successful treatment, respectively.
 ...
PMID:[Alpha herpesvirus infections in AIDS patients]. 1077 17

The most common therapies against human herpes virus (HSV-1) and human immunodeficiency virus (HIV-1) infectivity are based on the administration of nucleoside analogues. Acyclovir (ACV) is the drug of choice against HSV-1 infection, while the acyclic nucleoside phosphonate analogue PMPA has shown marked anti-HIV activity in a phase I and II clinical studies. As monocyte-derived macrophages are assumed to be important as reservoirs of both HSV-1 and HIV-1 infection, new approaches able to inhibit replication of both viruses in macrophages should be welcome. ACVpPMPA, a new heterodinucleotide consisting of both an antiherpetic and an antiretroviral drug bound by a phosphate bridge, was synthesized and encapsulated into autologous erythrocytes modified to increase their phagocytosis by human macrophages. ACVpPMPA-loaded erythrocytes provided an effective in vitro protection against both HSV-1 and HIV-1 replication in human macrophages.
 ...
PMID:A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus. 1097 67

The purpose of this study was to determine the frequency of HSV infections and recurrences among HIV-infected patients and to examine different regimens for suppression of HSV recurrence. A randomized retrospective chart review of HIV-infected patients at a public hospital in Los Angeles County was conducted. We reviewed 224 patients' charts; 26 percent had AIDS based on the 1987 CDC definition. HSV infection was documented as a clinical event in 51 records (23 percent). Patients with an AIDS diagnosis had a greater incidence (53 percent) of HSV infections than did those with a diagnosis of symptomatic or asymptomatic HIV infection (p < 0.001, Fisher's exact test). Recurrences of HSV occurred in 26 (51 percent) of the 51 HSV-infected persons during a period of 1042 patient months. Eighteen patients who had received acyclovir suppression at 600 mg/day had three HSV recurrences in 382 patient months, whereas 14 who received 400 mg/day had eight recurrences in 282 patient months (p = 0.02). HSV infections occur in 23 percent of HIV-infected patients, increasing to 53 percent in AIDS patients. Acyclovir suppression prevents recurrent HSV, and a dosage of 600 mg/day is more effective than 400 mg/day.
 ...
PMID:Prevention of recurrent herpes simplex virus (HSV) infections in HIV-infected persons. 1136 7

The virus that causes genital herpes affects 20 percent of the World's population. Among people with HIV, the incidence may be as high as 90 percent. All herpes viruses are formal candidates for the cofactor effect promoting HIV infection. People with unrecognized disease may account for many new cases. Only 20 percent of herpes seropositive persons recognize their herpes symptoms, 60 percent have unrecognized symptomatic disease, and 20 percent have subclinical, asymptomatic shedding of virus. Acyclovir shows promise of being effective in reducing herpes transmission, however, people with herpes should abstain from all sexual activity during symptomatic outbreaks, and at all other times use some sort of barrier protection. Acyclovir, in combination with AZT, is associated with survival benefits for people with AIDS, but new generations of antivirals may prove more effective in treating herpes. A post-infection vaccine, several of which are in development, may be even more promising.
 ...
PMID:On the herpes front. 1136 2

An HIV-infected person describes his self-directed treatment for AIDS. He explains his feelings and physical manifestations from the use of treatments such as AZT, ddC, aerosolized pentamidine, Septra, ddI, Zovirax, Trental, and combinations of drugs. The author also shares his experiences with weight lifting to increase his body mass. Currently, the 52-year-old, who has been HIV-positive since 1981, says he feels as good as he's ever felt in 15 years. He works out three times a week and says the results are better than he had hoped. He is now attempting to acquire 3TC which seems to work better than anything else to date when used in combination with AZT. According to the author, the best sources of knowledge are reading AIDS Treatment News, which he gets on his computer via a modem; calling the buyer's clubs in New York, Atlanta, etc.; and keeping a folder on Compuserve using the key word "AIDS" so that all the news articles containing the word AIDS are saved for him. He invites readers who have been living with HIV infection and AIDS for a number of years to write him and to tell him what they've been doing to stay alive. He concludes by saying that meditation has had a dramatic and positive effect on concentration, relaxation, and dealing with stress.
 ...
PMID:One person's story. 1136 91

Herpes is caused by a virus that causes recurring bouts of cold sores or genital lesions. The differences between herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) are explained. Herpes outbreaks can become harder to treat when the immune system is damaged by HIV. Acyclovir and famciclovir are safe and effective treatments, but preventing infection is especially important in HIV-infected individuals, as the amount of HIV in the blood increases during a herpes outbreak. World Wide Web addresses are provided for alternative herpes treatment information. A current trial is studying the effectiveness of acyclovir used with an antiviral gel, SP-303. Participants will be treated with acyclovir alone or with acyclovir and SP-303 gel. Call the Network for referral information.
 ...
PMID:Herpes study and resources. 1136 15

Our objective was to evaluate valaciclovir for anogenital herpes in HIV-infected individuals using 2 controlled trials conducted before highly active antiretroviral therapy (HAART) was used. In Study 1, 1062 patients (CD4+ > or = 100 cells/mm(3)) received suppressive valaciclovir or aciclovir for one year and were assessed monthly. In Study 2, 467 patients were treated episodically for > or =5 days with valaciclovir or aciclovir and evaluated daily. Valaciclovir was as effective as aciclovir for suppression and episodic treatment of herpes. Hazard ratios [95% confidence interval (CI)] for time to recurrence for valaciclovir 500 mg twice daily and 1000 mg once daily vs aciclovir were 0.73[0.50, 1.06], P=0.10, and 1.31[0.94, 1.82], P=0.11. Valaciclovir 500 mg twice daily was superior to 1000 mg once daily, P=0.001. Valaciclovir 1000 mg twice daily was comparable to aciclovir on herpes episode duration (hazard ratio 0.92[0.75, 1.14]). Adverse events were similar among treatments. In conclusion, valaciclovir is a safe, effective, convenient alternative to aciclovir for HSV infection in HIV-infected individuals.
 ...
PMID:Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. 1180 24


<< Previous 1 2 3 4 5 6 Next >>